Rodman & Renshaw Archives - Page 3 of 44

MondayNov 03, 2008 7:07 am

Inovio Biomedical Corporation (AMEX: INO)

Inovio Biomedical Corporation (AMEX: INO)Inovio Biomedical Corporation (AMEX: INO) has their focus on developing multiple DNA-based immunotherapies. The company is known as a leading developer of human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio's DNA delivery technology has demonstrated the ability to substantially increase gene expression and immune responses from DNA vaccines. For further information, visit the Company's web site at www.inovio.com.

MondayNov 03, 2008 7:07 am

Inhibitex, Inc. (NASDAQ: INHX)

Inhibitex, Inc. (NASDAQ: INHX) is a biopharmaceutical company engaging in the development of differentiated anti-infective products designed to prevent and treat serious infections. The company’s products include FV-100, a nucleoside analogue prodrug; HIV Integrase Inhibitors class of anti-retroviral agents; and a series of nucleoside and non-nucleoside HCV polymerase inhibitors designed to treat the hepatitis C virus. For further information, visit the Company's web site at www.inhibitex.com.

MondayNov 03, 2008 7:06 am

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), an innovative cancer drug discovery and development company, is focused on discovering, developing, and delivering best-in-class medicines designed to treat cancer and related conditions. The company leverages its proven scientific expertise and passion for developing novel small molecule drugs designed to target emerging cancer pathways. Infinity's two most advanced programs are examples of its innovative approach to oncology drug discovery and development. For further information, visit the Company's web site at www.infi.com.

MondayNov 03, 2008 7:05 am

India Globalization Capital, Inc. (AMEX: IGC)

India Globalization Capital, Inc. (AMEX: IGC) is a company that was formed to acquire operating businesses located in India through merger, capital stock exchange, asset acquisition or other similar business combination. India Globalization Capital (IGC) has three main competencies which are: Highway and Heavy Construction, Mining and Quarrying, and Civil Construction and Engineering of high-temperature plants. IGC is a step ahead of their competition because they are the only Indian infrastructure company listed and trading in the United States. For further information, visit the company

MondayNov 03, 2008 7:04 am

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV)

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), a specialty pharmaceutical company, is focused on the acquisition, development, and commercialization of products designed to treat conditions in urology and endocrinology. The company's approved products include SANCTURA® and SANCTURA XR(TM) for overactive bladder, SUPPRELIN® LA for central precocious puberty, VANTAS® for advanced prostate cancer, and DELATESTRYL® to treat male hypogonadism. For further information, visit the Company's web site at www.indevus.com.

MondayNov 03, 2008 7:04 am

ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC)

ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC), a clinical-stage company, is focused on developing new therapeutics to fight cancer using the human body’s immune system. Their product pipeline consists of cellular immunotherapies that target brain cancer, and monoclonal antibodies designed to diagnose and treat various cancers. The company’s lead product candidate is currently in a Phase I clinical trial to treat glioblastoma multiforme, the most common type of brain tumor. For further information, visit the Company's web site at www.imuc.com.

MondayNov 03, 2008 7:03 am

IR Biosciences Holdings Inc.’s (IRBS.OB)

IR Biosciences Holdings Inc.’s (IRBS.OB) subsidiary is a development-stage biotechnology company devoted to researching, developing and licensing Homspera® and its derivatives. Homspera is an adult stem cell active compound that has been demonstrated the ability to regenerate and strengthen the immune system as well as enhance wound healing. To further its mission, IR BioSciences has forged a number of study partnerships with industry and academic leaders. For more information, please visit www.immuneregen.com.

MondayNov 03, 2008 7:03 am

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) is focused on developing drug candidates that treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and can be used as vaccine adjuvants. The company’s pioneering DNA and RNA chemistry expertise enables them to develop drug candidates for internal development while creating opportunities for multiple collaborative alliances. For further information, visit the Company's web site at www.iderapharma.com.

MondayNov 03, 2008 7:02 am

ICU Medical, Inc. (NASDAQ: ICUI)

ICU Medical, Inc. (NASDAQ: ICUI), founded in 1984 by Dr. George Lopez, a practicing internist who believed there was a better way of securing I.V. lines, is focused on developing and manufacturing products that both protect the Health Care worker from accidental needle sticks as well as protect the reliability of IV systems. With an approximate market cap of nearly 500 million, ICU’s products include the CLAVE NeedleFree Connector and the CLC2000 Catheter Patency Device. For further information, visit the Company's web site at www.icumed.com.

MondayNov 03, 2008 7:01 am

Icagen, Inc. (NASDAQ: ICGN)

Icagen, Inc. (NASDAQ: ICGN) is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities, in some cases in collaboration with leading pharmaceutical companies, in a number of disease areas, including epilepsy, pain and inflammation. The Company has clinical stage programs in epilepsy and asthma. For further information, visit the Company's web site…

Site Search

Company Search

Tag: Rodman & Renshaw